ReviewFrontiers in aging2022
Clinical Trials Targeting Aging.
Review in Frontiers in aging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 47 citations in OpenAlex.
- Rescuing age-associated vaccine hyporesponsiveness in murine and nonhuman primate models with an immunostimulatory vaccine adjuvant.Human vaccines & immunotherapeutics · 2026Article
- Evaluation ofJMIR research protocols · 2026Article
- Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment.Nature biotechnology · 2026Article
- Comprehensive Geriatric Assessment in the Management of Frailty and Multimorbidity in Older Adults: A Systematic Literature Review.Journal of frailty, sarcopenia and falls · 2026Review
- Data and knowledge-driven imaging biomarkers for lumbar aging and degenerative risk stratification monitoring.NPJ digital medicine · 2026Article
- Microvascular Health as a Key Determinant of Organismal Aging.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Mining bioactive components in agricultural crop and food production residue for sustainable solutions: In silico screening for skin anti-ageing properties.International journal of cosmetic science · 2025Article
- Review
- Quantification of Epigenetic Aging in Public Health.Annual review of public health · 2025Review
- Astrocytes in aging.Neuron · 2025Review
- Review
- Clinical Insights on Caloric Restriction Mimetics for Mitigating Brain Aging and Related Neurodegeneration.Cellular and molecular neurobiology · 2024Review
- Ethical concerns in aging research: perspectives of global frontline researchers.Science China. Life sciences · 2024Article
- Promising Effects of Novel Supplement Formulas in Preventing Skin Aging in 3D Human Keratinocytes.Nutrients · 2024Article
- A Framework for an Effective Healthy Longevity Clinic.Aging and disease · 2024Review
- Longevity as a Responsibility: Constructing Healthy Aging by Enacting within Contexts over the Entire Lifespan.Geriatrics (Basel, Switzerland) · 2024Article
- The Impact of Immune System Aging on Infectious Diseases.Microorganisms · 2024Review
- Skin senescence-from basic research to clinical practice.Frontiers in medicine · 2024Review
- Phytonutrients in the promotion of healthspan: a new perspective.Frontiers in nutrition · 2024Review
- How is Big Data reshaping preclinical aging research?Lab animal · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The risk of morbidity and mortality increases exponentially with age. Chronic inflammation, accumulation of DNA damage, dysfunctional mitochondria, and increased senescent cell load are factors contributing to this. Mechanistic investigations have revealed specific pathways and processes which, proposedly, cause age-related phenotypes such as frailty, reduced physical resilience, and multi-morbidity. Among promising treatments alleviating the consequences of aging are caloric restriction and pharmacologically targeting longevity pathways such as the mechanistic target of rapamycin (mTOR), sirtuins, and anti-apoptotic pathways in senescent cells. Regulation of these pathways and processes has revealed significant health- and lifespan extending results in animal models. Nevertheless, it remains unclear if similar results translate to humans. A requirement of translation are the development of age- and morbidity associated biomarkers as longitudinal trials are difficult and not feasible, practical, nor ethical when human life span is the endpoint. Current biomarkers and the results of anti-aging intervention studies in humans will be covered within this paper. The future of clinical trials targeting aging may be phase 2 and 3 studies with larger populations if safety and tolerability of investigated medication continues not to be a hurdle for further investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.